Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02118571 · ClinicalTrials.gov registry record
Schizophrenia Cognition Scale Development
A clinical trial, sponsored by Carelon Research.
- Completed
- Registry status
- 102
- Enrollment target
NCT02118571: Completed study, sponsored by Carelon Research.
NCT02118571 is a clinical trial that has completed, run by Carelon Research. The registered enrollment target is 102 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02118571 has completed, sponsored by Carelon Research.
- COMPLETED
- Registry status
- 102 participants
- Enrollment target
Study Summary
The objective of this protocol is to develop items for a patient-reported outcome (PRO) measure to assess the patient's perspective and subjective experience of cognitive impairment associated with schizophrenia (CIAS).
Primary Outcome
Using qualitative interview methods, adult subjects with a diagnosis of schizophrenia will provide self reported experience of cognitive impairments associated with schizophrenia. Domains and content will be identified and explored with the subjects and used to develop the PRO measure.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2013-11 |
| Est. Completion | 2016-07 |
What the finished NCT02118571 record still lists
NCT02118571 is an observational study that tracks outcomes without assigning an intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02118571 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02118571 about?
NCT02118571 is a clinical study titled "Schizophrenia Cognition Scale Development". The objective of this protocol is to develop items for a patient-reported outcome (PRO) measure to assess the patient's perspective and subjective experience of cognitive impairment associated with schizophrenia (CIAS).
What is the current status of trial NCT02118571?
This trial is currently completed. The enrollment target is 102 participants. The study started on 2013-11. Estimated completion is 2016-07.
Who is sponsoring clinical trial NCT02118571?
This trial is sponsored by Carelon Research, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704662 · 102 participants · NA
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
- NCT04174742 · 102 participants
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
- NCT04275362 · 102 participants
Gait Analysis of a Lateral-Pivot Design Total Knee Replacement
- NCT04541082 · 102 participants · Phase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia